[1] Yamazaki T, Takahashi K, Bessho K. Recent clinical evidence in bisphosphonate-related osteomyelitis of the jaw: focus on risk, prevention and treatment[J]. Rev Recent Clin Trials, 2014, 9(1): 37-52.
[2] Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic[J]. J Oral Maxillofac Surg, 2003, 61(9): 1115-1117.
[3] 阮敏, 季彤, 张陈平. 双膦酸盐性颌骨坏死的研究进展[J]. 上海口腔医学, 2006, 15(6): 663-667.
[4] Migliorati CA, Casiglia J, Epstein J, et al. Managing the care of patients with bisphosphonate-associated osteonecrosis[J]. J Am Dent Assoc, 2005, 136(12): 1658-1668.
[5] Hellstein JW, Marek CL. Bisphosphonate osteochemonecrosis (bis-phossy jaw): is this phossy jaw of the 21st century [J] ? J Oral Maxillofac Surg, 2005, 63(5): 682-689.
[6] Boff RC, Salum FG, Figueiredo MA, et al. Important aspects regarding the role of microorganisms in bisphosphonate-related osteonecrosis of the jaws[J]. Arch Oral Biol, 2014, 59(8): 790-799.
[7] Lo JC, O'Ryan FS, Gordon NP, et al. Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure[J]. J Oral Maxillofac Surg, 2010, 68(2): 243-253.
[8] Bianchi SD, Scoletta M, Cassione FB, et al. Computerized tomographic findings in bisphosphonate-associated osteonecrosis of the jaw in patients with cancer[J]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2007, 104(2): 249-258.
[9] Ruggiero SL, Dodson TB, Assael LA, et al. American association of oral and maxillofacial surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update[J]. J Oral Maxillofac Surg, 2009, 67(5 Suppl): 2-12.
[10] 殷学民, 王方圆. 双膦酸盐性颌骨坏死的临床诊断与治疗[J]. 口腔疾病防治, 2017, 25(3): 137-142.
|